HUTCHMED (China) Limited

(HCM)
Sector: Pharmaceuticals & Biotechnology
278.00p
0.00p 0.00
Last updated: 10:28:52

Company News Headlines

Date Time Headline Source
20/11/2024 09:30 Appointment of Independent Non-executive Director RNS
31/10/2024 08:30 Total Voting Rights RNS
21/10/2024 09:30 Vesting of awards under the LTIP RNS
16/10/2024 07:00 SAVANNAH: clinically meaningful response rate RNS
24/09/2024 08:00 Japan Approval for FRUZAQLA RNS
30/08/2024 09:30 Total Voting Rights RNS
30/08/2024 07:00 Update on Fruquintinib for Gastric Cancer in China RNS
22/08/2024 09:30 Standard form for notification of major holdings RNS
06/08/2024 10:00 LTIP and Share Option Scheme RNS
31/07/2024 12:00 2024 Interim Results and Business Updates RNS
28/06/2024 09:30 Blocklisting Six Monthly Return RNS
28/06/2024 09:30 Total Voting Rights RNS
26/06/2024 09:30 HUTCHMED to Announce 2024 HY Financial Results RNS
24/06/2024 07:00 European Commission Approval for FRUZAQLA RNS
31/05/2024 09:30 Total Voting Rights RNS
17/05/2024 15:00 Retirement of Chairman and new Chairman appointed RNS
10/05/2024 13:00 Result of AGM RNS
08/05/2024 09:30 Directorate Change RNS
26/04/2024 13:30 Positive CHMP Opinion for Fruquintinib RNS
22/04/2024 09:30 Vesting of Awards Under the LTIP RNS
08/04/2024 09:30 2023 Annual Report and Notice of AGM RNS
14/03/2024 09:00 LTIP and Share Option Scheme RNS
05/03/2024 08:30 Vesting of awards under the LTIP RNS
28/02/2024 11:30 2023 Full Year Results and Business Updates RNS
01/02/2024 08:30 HUTCHMED to Announce 2023 Final Results RNS
29/12/2023 08:30 Total Voting Rights RNS
29/12/2023 08:30 Blocklisting Six Monthly Return RNS
21/12/2023 10:00 Overseas Regulatory Announcement RNS
07/12/2023 10:04 Overseas Regulatory Announcement RNS
30/11/2023 08:30 Total Voting Rights RNS
09/11/2023 07:00 U.S. FDA Approval of FRUZAQLAâ„¢ (fruquintinib) RNS
24/10/2023 09:30 Vesting of awards under the LTIP RNS
29/09/2023 09:30 Total Voting Rights RNS
14/09/2023 09:30 Director’s Share Dealing RNS
31/08/2023 09:30 Total Voting Rights RNS
21/08/2023 07:00 Sovleplenib Phase 3 Study Meets Primary Endpoint RNS
07/08/2023 09:30 Exercise of Share Options by a Director RNS
31/07/2023 12:00 Interim Results and Business Updates RNS
13/07/2023 09:30 Changes to Board and Technical Committee RNS
29/06/2023 09:30 Blocklisting Six Monthly Return RNS
26/06/2023 09:30 HUTCHMED to Announce 2023 Half-Year Results RNS
16/06/2023 07:00 Phase III FRESCO-2 Results in The Lancet RNS
15/06/2023 15:39 MAA of Fruquintinib Validated by the EMA RNS
06/06/2023 10:00 LTIP and Share Option Scheme RNS
31/05/2023 09:30 Total Voting Rights RNS
26/05/2023 07:00 Fruquintinib NDA Granted Priority Review by FDA RNS
17/05/2023 09:30 Standard form for notification of major holdings RNS
12/05/2023 13:15 Annual General Meeting Poll Results RNS
12/05/2023 09:30 Board of Directors and Board Committee Membership RNS
10/05/2023 09:30 Appointment of Independent NED RNS